Optimization of Soluble Gamma-secretase Modulators for the Treatment of Alzheimer

描述（申请人提供）：我们的项目的主要目标是优化，机械地表征（在最合适的分子中，细胞和转基因动物模型），并完成整个临床前开发（通过IND申请）的一种有效的口服生物可利用的治疗化合物，该化合物是从一系列新的最近发现的用于治疗阿尔茨海默病的γ-分泌酶调节剂（GSM）中仔细选择的（AD）。AD是影响与学习和记忆相关的大脑区域的神经退行性疾病。AD影响全世界超过2400万人，是社会的巨大负担。它对本港人口老化的影响程度，将会继续增加。最近发现了一系列芳基2-氨基噻唑γ-分泌酶调节剂（AGSM），它们是药物样小有机分子，能够降低A β 42的产生，而不会显著影响其他已知γ-分泌酶底物（如Notch-1受体）的分泌酶介导的酶促加工。本项目将重点研究一系列具有改善的理化性质的AGSM（SGSM）的药理学优化。如果在一些预测性临床前研究中取得成功，这些分子将进行进一步的IND临床前开发，并最终在人体中进行测试。

DESCRIPTION (provided by applicant): The broad goals of our project are to pharmacologically optimize, mechanistically characterize (in the most appropriate molecular, cellular and transgenic animal models) and complete the entire preclinical development (through IND filing) of a potent orally bioavailable therapeutic compound carefully selected from a novel series of recently discovered gamma-secretase modulators (GSMs) for the treatment of Alzheimer's disease (AD). AD is neurodegenerative disorder that affects regions of the brain associated with learning and memory. AD affects over 24 million people world-wide and is an enormous burden to society. The extent at which it will affect our aging population will continue to escalate. A recently discovered a series of aryl 2-aminothiazole gamma-secretase modulators (AGSMs) that are pharmaceutical-like small organic molecules that are able to lower Abeta42 production without measurably affecting -Secretase-mediated enzymatic processing of other known gamma-secretase substrates such as the Notch-1 receptor. This project will focus on the pharmacological optimization of a series of AGSMs with improved physicochemical properties known as SGSMs. If successful in a number of predictive preclinical studies, these molecules will undergo further IND-enabling preclinical development and ultimately be tested in humans.